Incomplete recovery at end of study № of participants: 766 (3 RCTs) · Bell's palsy
Antivirals plus corticosteroids showed no clear difference in incomplete recovery at end of study № of participants: 766 (3 RCTs) compared with corticosteroids plus placebo or no treatment (AS versus OS) (low certainty).
1 finding from 1 review
RR 0.81 [0.38, 1.74]
Studies not reported
Low
Motor synkinesis or crocodile tears № of participants: 469 (2 RCTs) · Bell's palsy
Antivirals plus corticosteroids probably leads to lower motor synkinesis or crocodile tears № of participants: 469 (2 RCTs) compared with corticosteroids plus placebo or no treatment (AS versus OS) (moderate certainty).
1 finding from 1 review
RR 0.56 [0.36, 0.87]
Studies not reported
Moderate
Adverse events № of participants: 656 (2 RCTs) · Bell's palsy
It is very uncertain whether antivirals plus corticosteroids changes adverse events № of participants: 656 (2 RCTs) compared with corticosteroids plus placebo or no treatment (AS versus OS) (very low certainty).
1 finding from 1 review
RR 1.17 [0.81, 1.68]
Studies not reported
Very low
Treatment failure ‐ need for systemic corticosteroids (ITT) · adults and children with chronic asthma
Increased showed no clear difference in treatment failure: need for systemic corticosteroids (ITT) compared with stable doses of inhaled corticosteroids (moderate certainty).
1 finding from 1 review
Treatment failure ‐ need for systemic corticosteroids (of those starting inhaler) · adults and children with chronic asthma
It is very uncertain whether increased changes treatment failure: need for systemic corticosteroids (of those… compared with stable doses of inhaled corticosteroids (very low certainty).
1 finding from 1 review
Death at final · primary membranous nephropathy in adults with nephrotic syndrome
Oral alkylating agents ± steroids showed no clear difference in death at final compared with placebo/no treatment/steroids (low certainty).
1 finding from 1 review
End‐stage renal disease · primary membranous nephropathy in adults with nephrotic syndrome
Oral alkylating agents ± steroids probably leads to lower end‐stage kidney disease at final compared with placebo/no treatment/steroids (moderate certainty).
1 finding from 1 review
Total remission (complete or partial) at final · primary membranous nephropathy in adults with nephrotic syndrome
Oral alkylating agents ± steroids probably leads to higher total remission (complete or partial) at final compared with placebo/no treatment/steroids (moderate certainty).
1 finding from 1 review
Complete remission · primary membranous nephropathy in adults with nephrotic syndrome
Oral alkylating agents ± steroids probably leads to higher complete remission at final compared with placebo/no treatment/steroids (moderate certainty).
1 finding from 1 review
Relapse · primary membranous nephropathy in adults with nephrotic syndrome
It is very uncertain whether oral alkylating agents ± steroids changes recurrence of disease (relapse) at final compared with placebo/no treatment/steroids (very low certainty).
1 finding from 1 review
100% increase in SCr at final · primary membranous nephropathy in adults with nephrotic syndrome
Oral alkylating agents ± steroids showed no clear difference in 100% increase in serum creatinine at final compared with placebo/no treatment/steroids (moderate certainty).
1 finding from 1 review
Adverse events ‐ temporary or permanent discontinuation/hospitalisation at final · primary membranous nephropathy in adults with nephrotic syndrome
Oral alkylating agents ± steroids may leads to higher adverse events ‐ temporary/permanent discontinuation or… compared with placebo/no treatment/steroids (low certainty).
1 finding from 1 review
Adverse events ‐ infection at 3 years · primary membranous nephropathy in adults with nephrotic syndrome
It is very uncertain whether oral alkylating agents ± steroids changes adverse events ‐ infection at 3 years compared with placebo/no treatment/steroids (very low certainty).
1 finding from 1 review
Adverse events: malignancy · primary membranous nephropathy in adults with nephrotic syndrome
It is very uncertain whether oral alkylating agents ± steroids changes adverse events ‐ malignancy at final compared with placebo/no treatment/steroids (very low certainty).
1 finding from 1 review
Death at final · primary membranous nephropathy in adults with nephrotic syndrome
It is very uncertain whether calcineurin inhibitors ± steroids changes death at final compared with placebo/no treatment/supportive treatment/steroids (very low certainty).
1 finding from 1 review
End‐stage renal disease · primary membranous nephropathy in adults with nephrotic syndrome
It is very uncertain whether calcineurin inhibitors ± steroids changes end‐stage kidney disease at final compared with placebo/no treatment/supportive treatment/steroids (very low certainty).
1 finding from 1 review
Total remission (complete or partial) at final · primary membranous nephropathy in adults with nephrotic syndrome
Calcineurin inhibitors ± steroids showed no clear difference in total remission at final compared with placebo/no treatment/supportive treatment/steroids (low certainty).
1 finding from 1 review
Complete remission · primary membranous nephropathy in adults with nephrotic syndrome
Calcineurin inhibitors ± steroids showed no clear difference in complete remission at final compared with placebo/no treatment/supportive treatment/steroids (low certainty).
1 finding from 1 review
Relapse · primary membranous nephropathy in adults with nephrotic syndrome
It is very uncertain whether calcineurin inhibitors ± steroids changes recurrence of disease (relapse) at final compared with placebo/no treatment/supportive treatment/steroids (very low certainty).
1 finding from 1 review
100% increase in SCr at final · primary membranous nephropathy in adults with nephrotic syndrome
It is very uncertain whether calcineurin inhibitors ± steroids changes 100% increase in SCr at final compared with placebo/no treatment/supportive treatment/steroids (very low certainty).
1 finding from 1 review